About Us

Indi Molecular has developed two oncology therapeutic lead molecules using a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs were originally created in collaboration with the California Institute of Technology using a unique and patented “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with remarkable precision and stability. These low molecular weight cyclic peptides are the basis for Indi Molecular’s two oncology drug candidates. 

The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors. In June 2017, the company announced the closing of a $11.5 million A round led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands) and Legend Capital of Beijing. The proceeds were used to establish a high throughput PCC discovery platform and to advance discovered leads against two oncology clinical indications: ovarian and pancreatic cancer.